Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: A retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study

Satoshi Kubo, Kazuyoshi Saito, Shintaro Hirata, Shunsuke Fukuyo, Kunihiro Yamaoka, Norifumi Sawamukai, Masao Nawata, Shigeru Iwata, Yasushi Mizuno, Yoshiya Tanaka

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy and safety in patients with rheumatoid arthritis (RA). Methods Fifty Japanese patients with RA were treated with abatacept for 24 weeks in routine clinical practice. Results At week 24, 20 % of patients achieved clinical remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 % were in remission or had a low disease activity. Structural remission [progression of modified total Sharp score (ΔmTSS) ≤0.5] was achieved in 76 % of patients. The ΔmTSS decreased significantly from 7.1 ± 7.3 at baseline to 1.8 ± 5.7 at week 24. C-reactive protein (CRP) was the only independent prognostic factor for joint damage progression at week 24, whereas SDAI and matrix metalloproteinase-3 levels were not. A very high proportion of patients with CRP levels <1.5 mg/dl (88 %) achieved structural remission. In terms of safety, the retention rate for all patients was favorable (80 %), and stomatitis was the only adverse event observed. No patient withdrew from the study because of infections. Conclusions Abatacept has favorable clinical and structural effects, inhibits radiographic progression, and has a good safety profile in routine clinical practice.

Original languageEnglish
Pages (from-to)42-51
Number of pages10
JournalModern Rheumatology
Volume24
Issue number1
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
C-Reactive Protein
Therapeutics
Joints
Safety
Matrix Metalloproteinase 3
Stomatitis
Patient Safety
Abatacept
Infection

Keywords

  • Abatacept
  • Japanese patients
  • Modified total Sharp score
  • Radiographic outcome
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Abatacept inhibits radiographic progression in patients with rheumatoid arthritis : A retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. / Kubo, Satoshi; Saito, Kazuyoshi; Hirata, Shintaro; Fukuyo, Shunsuke; Yamaoka, Kunihiro; Sawamukai, Norifumi; Nawata, Masao; Iwata, Shigeru; Mizuno, Yasushi; Tanaka, Yoshiya.

In: Modern Rheumatology, Vol. 24, No. 1, 2014, p. 42-51.

Research output: Contribution to journalArticle

Kubo, Satoshi ; Saito, Kazuyoshi ; Hirata, Shintaro ; Fukuyo, Shunsuke ; Yamaoka, Kunihiro ; Sawamukai, Norifumi ; Nawata, Masao ; Iwata, Shigeru ; Mizuno, Yasushi ; Tanaka, Yoshiya. / Abatacept inhibits radiographic progression in patients with rheumatoid arthritis : A retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. In: Modern Rheumatology. 2014 ; Vol. 24, No. 1. pp. 42-51.
@article{dc1fc8bc900b4411a2e769442182013e,
title = "Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: A retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study",
abstract = "Objectives Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy and safety in patients with rheumatoid arthritis (RA). Methods Fifty Japanese patients with RA were treated with abatacept for 24 weeks in routine clinical practice. Results At week 24, 20 {\%} of patients achieved clinical remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 {\%} were in remission or had a low disease activity. Structural remission [progression of modified total Sharp score (ΔmTSS) ≤0.5] was achieved in 76 {\%} of patients. The ΔmTSS decreased significantly from 7.1 ± 7.3 at baseline to 1.8 ± 5.7 at week 24. C-reactive protein (CRP) was the only independent prognostic factor for joint damage progression at week 24, whereas SDAI and matrix metalloproteinase-3 levels were not. A very high proportion of patients with CRP levels <1.5 mg/dl (88 {\%}) achieved structural remission. In terms of safety, the retention rate for all patients was favorable (80 {\%}), and stomatitis was the only adverse event observed. No patient withdrew from the study because of infections. Conclusions Abatacept has favorable clinical and structural effects, inhibits radiographic progression, and has a good safety profile in routine clinical practice.",
keywords = "Abatacept, Japanese patients, Modified total Sharp score, Radiographic outcome, Rheumatoid arthritis",
author = "Satoshi Kubo and Kazuyoshi Saito and Shintaro Hirata and Shunsuke Fukuyo and Kunihiro Yamaoka and Norifumi Sawamukai and Masao Nawata and Shigeru Iwata and Yasushi Mizuno and Yoshiya Tanaka",
year = "2014",
doi = "10.3109/14397595.2013.854051",
language = "English",
volume = "24",
pages = "42--51",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Abatacept inhibits radiographic progression in patients with rheumatoid arthritis

T2 - A retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study

AU - Kubo, Satoshi

AU - Saito, Kazuyoshi

AU - Hirata, Shintaro

AU - Fukuyo, Shunsuke

AU - Yamaoka, Kunihiro

AU - Sawamukai, Norifumi

AU - Nawata, Masao

AU - Iwata, Shigeru

AU - Mizuno, Yasushi

AU - Tanaka, Yoshiya

PY - 2014

Y1 - 2014

N2 - Objectives Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy and safety in patients with rheumatoid arthritis (RA). Methods Fifty Japanese patients with RA were treated with abatacept for 24 weeks in routine clinical practice. Results At week 24, 20 % of patients achieved clinical remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 % were in remission or had a low disease activity. Structural remission [progression of modified total Sharp score (ΔmTSS) ≤0.5] was achieved in 76 % of patients. The ΔmTSS decreased significantly from 7.1 ± 7.3 at baseline to 1.8 ± 5.7 at week 24. C-reactive protein (CRP) was the only independent prognostic factor for joint damage progression at week 24, whereas SDAI and matrix metalloproteinase-3 levels were not. A very high proportion of patients with CRP levels <1.5 mg/dl (88 %) achieved structural remission. In terms of safety, the retention rate for all patients was favorable (80 %), and stomatitis was the only adverse event observed. No patient withdrew from the study because of infections. Conclusions Abatacept has favorable clinical and structural effects, inhibits radiographic progression, and has a good safety profile in routine clinical practice.

AB - Objectives Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy and safety in patients with rheumatoid arthritis (RA). Methods Fifty Japanese patients with RA were treated with abatacept for 24 weeks in routine clinical practice. Results At week 24, 20 % of patients achieved clinical remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 % were in remission or had a low disease activity. Structural remission [progression of modified total Sharp score (ΔmTSS) ≤0.5] was achieved in 76 % of patients. The ΔmTSS decreased significantly from 7.1 ± 7.3 at baseline to 1.8 ± 5.7 at week 24. C-reactive protein (CRP) was the only independent prognostic factor for joint damage progression at week 24, whereas SDAI and matrix metalloproteinase-3 levels were not. A very high proportion of patients with CRP levels <1.5 mg/dl (88 %) achieved structural remission. In terms of safety, the retention rate for all patients was favorable (80 %), and stomatitis was the only adverse event observed. No patient withdrew from the study because of infections. Conclusions Abatacept has favorable clinical and structural effects, inhibits radiographic progression, and has a good safety profile in routine clinical practice.

KW - Abatacept

KW - Japanese patients

KW - Modified total Sharp score

KW - Radiographic outcome

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84904975988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904975988&partnerID=8YFLogxK

U2 - 10.3109/14397595.2013.854051

DO - 10.3109/14397595.2013.854051

M3 - Article

C2 - 24261758

AN - SCOPUS:84904975988

VL - 24

SP - 42

EP - 51

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 1

ER -